Format

Send to

Choose Destination
Hum Vaccin Immunother. 2018 Feb 1;14(2):412-419. doi: 10.1080/21645515.2017.1403702. Epub 2017 Dec 14.

Postlicensure safety surveillance of congenital anomaly and miscarriage among pregnancies exposed to quadrivalent human papillomavirus vaccine.

Author information

1
a Department of Research and Evaluation , Kaiser Permanente Southern California , Pasadena , CA , USA.
2
b Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California , Oakland , CA , USA.
3
c Department of Epidemiology , Merck Research Laboratories , Upper Gwynedd , PA , USA.
4
d Department of Pediatrics and Pediatric Infectious Diseases , Southern California Permanente Medical Group , Harbor City , CA , USA.

Abstract

Limited safety data are available on inadvertent exposure to quadrivalent human papillomavirus vaccine (4vHPV) during pregnancy. We conducted a descriptive observational postlicensure safety surveillance study in Kaiser Permanente Southern California and Northern California to assess congenital anomaly and miscarriage among pregnancies exposed to 4vHPV. Using electronic medical records, we identified women who received a dose of 4vHPV between August 2006 and March 2008 within 30 days preconception or any time during a possible pregnancy. A broad algorithm was developed using diagnostic and procedure codes and laboratory tests to identify pregnancy, congenital anomalies, and miscarriages. Medical records of all potential congenital anomaly cases and a random sample of 100 potential miscarriage cases were reviewed to confirm pregnancy exposure and diagnosis. Results were reviewed by an independent Safety Review Committee (SRC). Among the population of 189,629 females who received at least one dose of 4vHPV during the study period, 2,678 females were identified as possibly having a 4vHPV-exposed pregnancy. Among 170 potential congenital anomalies identified, 44 (26%) were found to be both 4vHPV-exposed and confirmed congenital anomaly cases. Among the 633 potential miscarriages identified, the records of a random sample of 100 cases were reviewed, and 9 cases (9%) were confirmed as 4vHPV-exposed miscarriages. The SRC noted no safety signal for congenital anomaly or miscarriage associated with 4vHPV exposure during pregnancy. The rate of major congenital anomaly (3.6%) was in the range of background estimates from the literature. There was no apparent pattern of timing of 4vHPV exposure among 4vHPV-exposed miscarriages.

KEYWORDS:

papillomavirus vaccines; pharmacovigilance; postmarketing product surveillance; pregnancy outcome; safety

PMID:
29140750
PMCID:
PMC5806640
[Available on 2018-12-14]
DOI:
10.1080/21645515.2017.1403702

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center